Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-05-18
2011-12-06
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S158100
Reexamination Certificate
active
08071098
ABSTRACT:
An objective of the present invention is to provide a cerebral vasospasm inhibitor which is effective on cerebral vasospasm occurring after subarachnoid hemorrhage and has few side-effects. The cerebral vasospasm inhibitor of the invention is characterized in containing an anti-HMGB1 monoclonal antibody as an active ingredient.
REFERENCES:
patent: 5770772 (1998-06-01), Aono et al.
patent: 6004986 (1999-12-01), Arthur et al.
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6468533 (2002-10-01), Tracey et al.
patent: 6610713 (2003-08-01), Tracey et al.
patent: 6646006 (2003-11-01), Cooke et al.
patent: 6838471 (2005-01-01), Tracey et al.
patent: 7060504 (2006-06-01), Tracey et al.
patent: 7097838 (2006-08-01), Tracey et al.
patent: 7125567 (2006-10-01), Sugi et al.
patent: 7220723 (2007-05-01), Tracey et al.
patent: 7288250 (2007-10-01), Newman et al.
patent: 7304034 (2007-12-01), Tracey et al.
patent: 2002/0102609 (2002-08-01), Tracey et al.
patent: 2003/0017155 (2003-01-01), Tracey et al.
patent: 2003/0060410 (2003-03-01), Tracey et al.
patent: 2003/0113323 (2003-06-01), Tracey et al.
patent: 2004/0005316 (2004-01-01), Tracey et al.
patent: 2006/0035851 (2006-02-01), Bianchi et al.
patent: 2006/0210565 (2006-09-01), Tracey et al.
patent: 2006/0240019 (2006-10-01), Tracey et al.
patent: 2008/0305073 (2008-12-01), Barone et al.
patent: 2002-60346 (2002-02-01), None
patent: 2003-520763 (2003-07-01), None
patent: 2004-510695 (2004-08-01), None
patent: 2005-120070 (2005-05-01), None
patent: 2005-512507 (2005-05-01), None
patent: 2005-537253 (2005-12-01), None
patent: 3882090 (2007-02-01), None
patent: 00/47104 (2000-08-01), None
patent: 02/092004 (2002-11-01), None
patent: 2004/004763 (2004-01-01), None
patent: 2006/124477 (2006-11-01), None
Tachikawa et al., J. Nihon Univ. Med. Ass. 62: 469-479, 2002.
International Search Report issued Jun. 12, 2007 in the International (PCT) Application No. PCT/JP2007/060231 of which the present application is the U.S. National Stage.
European Search Report issued Apr. 23, 2009 in the European patent Application No. 07743666.5 which is a counterpart of the present application.
Isao Date, et al., “Gene therapy against cerebral vasospasm after subarachnoid hemorrhage”, Brain and Circulation; Medical View Co., Ltd., published in 2002, vol. 7, No. 1, pp. 47-51 ISSN 1341-8440, with a Brief explanation of the document in English.
Ikuro Maruyama, “Surgical trauma in living body and HMGB1: delayed biological lethal factor”, Surgical Trauma and Immunity; Medical Review Co., Ltd., published in 2006, pp. 31-36 with a Brief explanation of the document in English.
George Bowman, et al. “A Novel Inhibitor of Inflammatory Cytokine Production (CNI-1493) Reduces Rodent Post-Hemorrhagic Vasospasm” Neurocritical Care, Humana Press, Totowa, NJ, US, vol. 5, No. 3, published Jan. 1, 2006, pp. 222-229.
Sajjad Muhammad, et al. “The HMGB1 Receptor RAGE Mediates Ischemic Brain Damage” Journal of Neuroscience, New York, NY, US, vol. 28, No. 46, published Nov. 1, 2008, pp. 12023-12031.
Extended European Search Report issued Dec. 7, 2009 in related European Application No. 06811724.1.
K. Liu et al., “Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats”, The FASEB Journal, vol. 21, No. 14, pp. 3904-3916, Dec. 2007.
Reply to the ISR (plus English translation) filed in related application No. PCT/JP2006/320436.
English translation of “Certified Experiment Results”, as referenced on p. 9 of the “Reply to the ISR” (see above).
E. Abraham et al., “Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation”, The Journal of Immunology, The American Association of Immunologists (2000), vol. 65, pp. 2950-2954.
H. Yang et al., “The Cytokine Activity of HMGB1”, Journal of Leukocyte Biology, Jul. 2005, vol. 78, No. 1, pp. 1-8.
K.A. O'Connor et al., “Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects”, Cytokine (2003), vol. 24, pp. 254-265.
N. Vila et al., “Proinflammatory cytokines and early neurological worsening in ischemic stroke”, Stroke (2000), vol. 31, No. 10, pp. 2325-2329.
SL. Liao et al., “Association of Immune Responses and Ischemic Brain Infarction in Rat”, Neuroreport (2001), vol. 12, No. 9, pp. 1943-1947.
Office Action dated Sep. 3, 2009 in U.S. Appl. No. 12/084,044, the national stage application to related application No. PCT/JP2006/320436.
International Search Report and PCT/IB/338 in related application No. PCT/JP2006/320436.
International Search Report and PCT/IB/338 of corresponding application No. PCT/JP2007/060231.
Reply to the ISR (plus English translation) filed in the corresponding application No. PCT/JP2007/060231.
English translation of “Certified Experiment Results”.
“Explanation of Circumstances Concerning Accelerated Examination” (English translation) filed in related application No. JP 2005-308949.
“Notice of Reasons for Refusal” dated May 30, 2006 issued in related application No. JP 2005-308949.
A. Williams et al., “Delayed Treatment of Ischemia/Reperfusion Brain Injury”, Stroke (2004), vol. 35, No. 5, pp. 1186-1191.
R. Berti et al., “Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury”, Journal of Cerebral Blood Flow and Metabolism (2002), vol. 22, No. 9, pp. 1068-1079.
Koroshetz, Walter J. and Michael A. Moskowitz, “Emerging treatments for stroke in humans”, Journal of Cerebral Blood Flow and Metabolism, Sep. 2002, vol. 22, No. 9, pp. 227-233.
European Office Action issued Oct. 6, 2010 in European Application 06811724.1 corresponding to CIP U.S. Appl. No. 12/654,790.
Y. Yamasaki et al., “Interleukin-1 as a Pathogenetic Mediator of Ischemic Brain Damage in Rats,”Stroke, vol. 26, No. 4, pp. 676-681, 2005.
F.C. Barone et al., “Tumor Necrosis Factor-α: A Mediator of Focal Ischemic Brain Injury,”Stroke, vol. 28, No. 6, pp. 1233-1244, 1997.
A. Mizuno et al., “Inhibitory Effect of MCI-186, a Free Radical Scavenger, on Cerebral Ischemia Following Rat Middle Cerebral Artery Occlusion,”General Pharmacology, vol. 30, No. 4, pp. 575-578, 1998.
M.E. Sughrue et al., “Review: Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: A critical review of the literature,”Inflammation Research, vol. 53, pp. 497-508, 2004.
Chinese Office Action dated Feb. 1, 2011 issued in corresponding Chinese Patent Application No. 200780018253.X.
Office Action dated Mar. 22, 2011 issued in the related U.S. Appl. No. 12/654,790.
European Office Action issued Aug. 11, 2011 in related European Application No. 06 811 724.1.
Date Isao
Mori Shuji
Nishibori Masahiro
Ono Shigeki
Takahashi Hideo
Gambel Phillip
National University Corporation Okayama University
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Method of preventing cerebral vasospasm with anti-HMGB1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preventing cerebral vasospasm with anti-HMGB1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing cerebral vasospasm with anti-HMGB1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272542